India's drugs for domestic use fall short in quality tests, task force says

Medicines produced in India for domestic consumption are failing quality tests performed by a government task force set up to investigate poor manufacturing practices.

The country's Department of Pharmaceuticals set up the investigative group in 2014 with reps from the country's Ministry of Health and Family Welfare, the Drug Controller General of India, the Department of Commerce, the Department of Industrial Policy and Promotion and various industry groups, according to a report in the Hindustan Times.

One of the main drivers of the task force has been an increase in U.S. Food and Drug Administration oversight of Indian companies and a rise in warning letters and outright bans on drugs manufactured by a host of Indian companies.

The report said at least 13 warning letters were sent to Indian companies last year including letters to Sun Pharmaceuticals, Wockhardt, Cadila Healthcare and Dr. Reddy's Laboratories ($RDY).

The task force said in the report that in addition to quality control problems, it found "unethical administrative clearances" in some cases on drugs for domestic use and said India should "participate in the development of global regulatory standards."

- here's the report from the Hindustan Times

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.